Table 1.
Characteristics of Each Treatment Group at 4 Weeks After Transplantation
| Variable | MSC group, n=27 | Control group, n=27 |
|---|---|---|
| Age, y | 50.2±14.0 | 50.0±15.5 |
| Male sex, n (%) | 24 (88.9) | 20 (74.0) |
| Body weight, kg | 79.0±15.5 | 79.0±13.6 |
| BMI, kg/m2 | 25.8±3.6 | 25.0±4.0 |
| Primary diagnosis, n (%) | ||
| Hypertension | 3 (11.1) | 9 (33.3) |
| Polycistic kidney disease | 9 (33.3) | 3 (11.1) |
| IgA nephropaty | 6 (22.2) | 3 (11.1) |
| Diabetes | 5 (18.5) | 0 (0) |
| Reflux nephropathy | 0 (0) | 2 (7.4) |
| Membranous nephropathy | 1 (3.7) | 1 (3.7) |
| Lupus nephritis | 1 (3.7) | 0 (0) |
| Other | 1 (3.7) | 3 (11.1) |
| Unknown | 1 (3.7) | 6 (22.2) |
| SBP, mm Hg | 143.7±14.7 | 145.5±12.9 |
| DBP, mm Hg | 87.2±11.0 | 87.3±10.8 |
| MBP, mm Hg | 106.0±10.3 | 106.7±9.3 |
| BP >140/90 mm Hg | 18 (66.7) | 21 (77.8) |
| eGFR, mL/min per 1.73 m2 | 60.8±16.1 | 45.9±10.9 |
| Concomitant cardiovascular medications | ||
| Calcium‐channel blocker, n (%) | 18 (66.7) | 19 (70.4) |
| ACE‐I/ARB, n (%) | 11 (40.7) | 4 (14.8) |
| β‐Blocker, n (%) | 10 (37) | 10 (37) |
| Thiazide diuretic, n (%) | 0 (0) | 4 (14.8) |
| α‐Blocker, n (%) | 3 (11.1) | 1 (3.7) |
| Antihypertensive drugs ≥2, n (%) | 15 (55.6) | 11 (40.7) |
| Statin, n (%) | 7 (27.9) | 10 (37) |
| Insulin (%) | 6 (22.2) | 0 (0) |
ACE‐I indicates angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; BP, blood pressure; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate, calculated by the Chronic Kidney Disease Epidemiology Collaboration formula; IgA, immunoglobulin A; MBP, mean blood pressure; MSC, mesenchymal stromal cells; and SBP, systolic blood pressure.